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Abstract
Fas ligand is a potent inducer of apoptosis in human glioma cells by the FasrFas ligand pathway. With comparable
efficiency, metalloprotease inhibitors including puromycin and bestatin induce apoptosis in glioma cells. To evaluate the
involvement of potential components involved in Fas ligand- and metalloprotease inhibitor-induced apoptosis, we
investigated the effect of anti human Fas antibody, soluble Fas ligand and puromycin on cultures of human malignant
 .glioma cell lines LN-18, LN-229, T98G . Stimulation with Fas ligand lead to apoptotic cell death within 16 h.
Costimulation with the translational inhibitor cycloheximide and the transcription blocker actinomycin D did not reduce Fas
ligand toxicity. In contrast, apoptosis induced by puromycin was blocked by cycloheximide and decreased by subtoxic
doses of actinomycin D in all three gliomas. Whereas inhibition of caspase activity with the general inhibitor zVAD-fmk
resulted in a complete block of Fas ligand-induced cell death, puromycin-mediated apoptosis was found to be unaffected by
 .zVAD-fmk as well as by more specific inhibitors for caspase-1 Interleukin-1 b converting enzyme and caspase-3
 .CPP32rYama . Other prominent components involved in many apoptotic pathways as bcl-2 and reactive oxygen
intermediates were also examined. Bcl-2 which protects glioma cells from Fas ligand-induced cell death, was shown to have
only a small protective effect on puromycin-induced apoptosis. The tested radical scavengers did not reduce Fas- or
puromycin-mediated killing of human glioma cells. q 1997 Elsevier Science B.V.
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1. Introduction
 .Induction of apoptosis by Fas ligand FasL through
binding to its cell surface receptor Fas has been
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Fas antibody; BPN, N-tert.-butyl-a-phenyl-nitrone; CHX, cyclo-
heximide; FasL, Fas ligand; HSP, heat shock proteins; ICE,
interleukin-1 b converting enzyme; NAC, N-acetyl-L-cystein;
PCD, programmed cell death; PM, puromycin; ROI, reactive
oxygen intermediates
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shown to be an effective way to induce programmed
 .cell death PCD in several different cell types. In the
treatment of human gliomas, induction of apoptosis
by the FasrFasL system has been suggested as an
effective way to eliminate tumor cells. Human malig-
nant glioma cells are also forced into apoptosis by
 .metalloprotease inhibitors including puromycin PM
and bestatin. PM exerts multiple effects on very
different components of the cellular metabolism and
signal transduction machinery. Dependent on dosage,
w xPM has been shown to inhibit protein synthesis 1,2 ,
irreversibly block the activity of several enzymes
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including aminopeptidases and acetylcholinesterases
w x w x3–6 , induce c-myc RNA superinduction 7,8 , in-
w xhibit protein import into mitochondria 9 , or confer
w xthermoresistance to selected types of cells 10,11 .
The mechanism of action of PM is well established
for some of these phenomenons but less well charac-
terized for others. In protein synthesis for example,
PM acts as an analogue of aminoacyl-tRNA leading
to premature release of nascent polypeptide chains
w x12 . Inhibition of aminopeptidases has been shown to
w xbe competitive 13,14 while action on acetylcholin-
esterase activity has been found to be noncompetitive
w x15,16 . Superinduction refers to augmentation and
stabilization of mRNA levels through the action of
PM which at high dosage affects protein synthesis.
Another mechanism of superinduction is operative
when using PM at low levels not affecting protein
w xsynthesis 8 . Inhibition of protein import into mito-
chondria and induction of thermotolerance can both
be caused by PM. The compound acts on completely
distinct pathways involving either ATP-dependent
steps inside the inner mitochondrial membrane or
increased synthesis of stress proteins of the HSP
w xfamily respectively 9,10 . To learn more about the
mechanisms involved in induction of apoptosis in
human malignant gliomas, we investigated the func-
tional role of molecules known to regulate PCD for
their influence on apoptosis of gliomas induced by
low doses of PM in comparison to apoptosis induced
by the FasrFasL system.
2. Material and methods
2.1. Materials
The human glioma cell lines LN-18 and LN-229
were kindly provided by Dr. N. Tribolet Lausanne,
.Switzerland . T98G human glioma cells were ob-
 .tained from ATCC Rockville, MD . Bcl-2 overex-
pressing cells were generated by transfecting human
w xmalignant glioma cell lines 17 . G418 was purchased
 .from Gibco BRL Basel, Switzerland . The reagents
for in situ DNA end labeling were purchased from
 .Boehringer Mannheim Germany . PM, actinomycin
 .  .D ActD and cycloheximide CHX were obtained
 .from Fluka Switzerland , anti-human Fas mono-
 .clonal antibody a Fas Ab was from Kamiya
 .Thousand Oaks, CA . The caspase inhibitors acetyl-
 .Tyr-Val-Ala-L-Asp-aldehyde Ac-YVAD-cho ,
acetyl-Tyr-Val-Ala-L-Asp-chloromethylketone Ac-
.YVAD-cmk , acetyl-Asp-Glu-Val-L-Asp-aldehyde
 .Ac-DEVD-cho , and benzyloxycarbonyl-Val-Ala-
 .DL-Asp-fluoromethylketone zVAD-fmk were from
 .  .Bachem Switzerland , N-Acetyl-L-cysteine NAC
 .and N-tert.-butyl-a-phenyl-nitrone BPN were from
 .Sigma St. Louis, MO , and Alamar Blue was pur-
 .chased from Biosource Lucerna-Chem, Switzerland .
FasL and control supernatants were generated by
Neuro-2a cells transfected with mouse FasL cDNA or
w xwith the vector alone, respectively 18 . Treatment of
cells with FasL in combination with the radical scav-
engers NAC and BPN was performed using previ-
ously concentrated FasL.
2.2. Cell culture
Cells were cultured in DMEM containing 10%
FCS, 2 mM glutamine, 100 Urml penicillin and
w x100 mgrml streptomycin as described previously 17 .
Cells transfected with bcl-2 were maintained in
 .medium supplemented with G418 500 mgrml . For
the treatment of cells with inhibitors, serum content
in the culture medium was reduced to 0.5%.
2.3. Cell ˝iability
Cell viability assays were performed in microtiter-
 .plates Falcon 3072 . Viability of the cells exposed to
a Fas Ab, FasL or PM was measured after 16 h by
incubation further with Alamar Blue for 3 h. Extinc-
 .tion was read on a CytoFluor 2350 Millipore . Stain-
ing of the adherent cells was done with crystal violet
and absorption was measured on an ELISA reader at
540 nm.
2.4. In situ DNA end labeling
Cells were plated onto Labtek 8-well chamber
slides and cultured in serum-reduced culture medium.
Incorporation of biotinylated deoxyuridine triphos-
 .phate 50 mM was performed using terminal trans-
 .ferase 0.25 Urml followed by a streptavidine-
alkaline phosphatase detection system as described
w x17 .
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3. Results
To investigate the involvement of putative intra-
cellular regulators of PCD in PM-induced apoptosis,
we examined cellular activity, morphology and cell
survival of the human malignant glioma cell lines
LN-18, LN-229 and T98G after treatment with vary-
ing dosages of PM from 0.1 mM to 20 mM. Evalua-
tion of the importance of protein synthesis, Bcl-2,
 .caspases, or reactive oxygen intermediates ROI was
done by pre- and coincubation of specific inhibitors
in the case of protein synthesis, caspases and ROI, or
by overexpression of bcl-2 in transfected glioma cell
lines. For comparison, all the inhibitors used were
tested in parallel on their influence on apoptosis
induced by FasL and a Fas Ab, the apoptotic path-
way being described to be regulated by caspase-1
 .ICE and bcl-2.
3.1. Effect of puromycin on human gliomas
Cultured human malignant glioma cell lines LN-
.18, LN-229, T98G were killed by PM in a dose-de-
  ..pendent manner Fig. 1 A . The concentration of PM
 .  .  .Fig. 1. A Cycloheximide CHX and actinomycin D ActD
block and reduce PM-induced apoptosis respectively. LN-18 cells
were cultured to 90% confluency and stimulated with varying
concentrations of PM with or without CHX or ActD for 16 h.
Cell survival was measured by crystal violet staining in reference
to control cultures treated with CHX or ActD in the absence of
PM. Error bars show standard deviation of mean values of
triplicate measurements. – I – PM, - - ’ - - PM and CHX
 .  .  .10 mgrml , - - B - - PM and ActD 0.5mgrml . B CHX and
ActD enhance cytotoxicity of anti human Fas antibody a Fas
.  .Ab on glioma cells. Human glioma cells T98G were treated for
24 h with up to 1mgrml monoclonal a Fas Ab alone, or together
with CHX or ActD. Comparable results were obtained with the
other cell lines LN-18 and LN-229. Controls and error bars as in
 .Fig. 1 A . – I – a Fas Ab, - - ’ - - a Fas Ab and CHX
 .  .  .10 mgrml , - - B - - a Fas Ab and ActD 0.5mgrml . C In situ
 .DNA end labeling TUNEL of PM- and a Fas Ab-stimulated
human glioma cells confirms apoptotic cell death. TUNEL assay
was performed 16 h after stimulation of LN-18 cells with 10 mM
PM or 1mgrml a Fas Ab. The number of positively stained
floating cells were compared to the total number of cells in the
stimulated cell. Comparable results were obtained with LN-229
and T98G cells. Error bars show standard deviation of mean
values of three experiments.
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 .needed to kill 50% of the cells within 16 h 5–7 mM
was comparable to the amount needed to force other
 .cell lines JURKAT, LAN-1, COS-7 into apoptosis
 .data not shown . After 16 h of 10 mM PM treatment,
up to 90% of the cells detached from the culture plate
surface compared to 60% after treatment with
1 mgrml a Fas Ab and about 10% of the culture
medium-treated cells. The correlation between loss of
cell adherence and PCD was confirmed by in situ
 .DNA end labeling TUNEL . TUNEL staining was
found to be positive in more than 90% of the de-
 .tached cells Fig. 1 C . Furthermore, agarose gel elec-
trophoresis of cellular DNA isolated after 16 h of PM
incubation revealed the characteristic internucleoso-
mal cleavage pattern.
3.2. Effect of actinomycin D and cycloheximide on
puromycin- and Fas-mediated apoptosis
Addition of the transcriptional inhibitor ActD
 .0.5 mgrml and the translational blocker CHX
 .10 mgrml lead to lower killing rates in the case of
ActD and to a complete block of induction of apopto-
sis upon costimulation of the cells with PM and CHX
  ..Fig. 1 A . Addition of increasing amounts of ActD
and CHX lead to higher protection. Above critical
levels of the inhibitors, blockage of the protein syn-
thesis pathway caused toxic effects with decreased
cell proliferation and cell survival. The effects of
CHX and ActD were observed not only in LN-18 but
also when using the LN-229 or T98G cells. For
comparison, the same human glioma cell lines were
coexposed to either ActD or CHX, together with
 .varying concentrations 0.01–1 mgrml of mono-
clonal a Fas Ab. In Fas-mediated apoptosis of the
cell lines tested, an increase in cell killing of up to
 .40% in the presence of ActD 0.5 mgrml and of up
 .to 70% in the presence of CHX 10 mgrml was
observed at a Fas Ab-concentrations of 0.3 mgrml
  ..Fig. 1 B . Because of the high killing efficiency of
the FasL supernatant on the cell lines tested, addition
of ActD or CHX did not increase the amount of cell
death after 16 h.
 .Fig. 2. Whereas bcl-2 overexpression confers resistance to Fas ligand FasL -induced apoptosis, bcl-2 does only minimally affect
 .PM-induced apoptosis. LN-18 cells transfected with a bcl-2 overexpressing construct LN-18 bcl-2 were compared to control transfected,
 .neomycin resistant cells LN-18 neo . Apoptosis was induced by 16 h-incubations with various concentrations of PM and FasL and
assessed as described in legend to Fig. 1. – I – PM-treatment of LN-18 neo; – B – and of LN-18 bcl-2 cells; — ^ — treatment with
FasL of LN-18 neo cells; — ’ — and of LN-18 bcl-2 cells.
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3.3. Influence of o˝erexpression of bcl-2 on apoptosis
induced by puromycin and Fas ligand
Overexpression of bcl-2 in all three human glioma
 .cell lines LN-18, LN-229, T98G reduced the cyto-
toxicity of PM, although to a much lesser extent than
 .apoptosis induced by FasL Fig. 2 . The dose re-
sponse curve showed maximum protection by bcl-2
of 80% at FasL supernatant concentrations of 7%.
The respective value for PM treated cells was 20%
 .protection after addition of 10 mM PM Fig. 2 .
Likewise bcl-2 was able to interfere with stau-
 .rosporine-induced apoptosis data not shown .
3.4. In˝ol˝ement of caspases in puromycin- and Fas
ligand-induced apoptosis
Involvement of caspases in PM- and FasL-induced
apoptosis was tested by pre- and coincubation of the
cells with specific tetrapeptide inhibitors of caspase-1
ICE: peptide inhibitors Ac-YVAD-cho and Ac-
.YVAD-cmk and of caspase-3 proteases
 .CPP32rYama: inhibitor Ac-DEVD-cho , and with
the more general caspase inhibitor zVAD-fmk. PM-
induced apoptosis was neither inhibited by the three
specific inhibitors for caspase-1 and caspase-3 nor by
  ..the general caspase inhibitor Fig. 3 A . To ensure
that the concentrations of the caspase inhibitors were
sufficient to protect the cells from apoptosis induced
by proper stimuli, LN-18 and LN-229 cells were
treated with up to 500 mM of the caspase inhibitors
1 h before and during exposure to FasL. Addition of
) 10 mM of zVAD-fmk lead to a complete block of
FasL-induced apoptosis after 16 h. Incubation with
the tetrapeptide-inhibitors specific for caspase-1
 .  .Ac-AVAD-cmk and for caspase-3 Ac-DEVD-cho
increased cell survival by about 10% and 20% re-
spectively compared to Neo supernatant-treated cells
  ..Fig. 3 B .
3.5. Reacti˝e oxygen intermediates in puromycin-
and Fas ligand-induced apoptosis
ROI have been discussed as mediators of apoptotic
cell death induced by a number of cytotoxic agents.
Dependent on the cells examined and the apoptotic
stimulus used, radical scavengers were shown to
inhibit the cell death pathway. In the human glioma
 .Fig. 3. A Caspase inhibitors have no effect on PM-induced cell
death. LN-18 cells were preincubated for 1 h with the indicated
amounts of the general caspase inhibitor zVAD-fmk, the caspase-1
tetrapeptide inhibitor Ac-YVAD-cmk, and the caspase-3 inhibitor
Ac-DEVD-cho. After preincubation, cells were stimulated for
16 h with 5mM PM in presence of the varying amounts of the
inhibitors. For comparison, a dose response curve to PM is
 .shown – I – . Cell survival was determined as in Fig. 1. – I –
PM, – ’ – 5mM PM and zVAD-fmk, – B – 5mM PM and
 .Ac-YVAD-cmk, – v – 5mM PM and Ac-DEVD-cho. B In-
hibitors of caspase-1 and caspase-3 and a general caspase in-
hibitor reduce and block FasL-induced cell death. LN-18 cells
 .were treated as in Fig. 3 A . – I – FasL, – ’ – 5% FasL and
zVAD-fmk, – B – 5% FasL and Ac-YVAD-cmk, – v – 5%
FasL and Ac-DEVD-cho.
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Fig. 4. Radical Scavengers fail to inhibit PM-induced apoptosis.
 .  .After preincubation with NAC 5 mM or BPN 20 mM for
15 min, LN-18 cells were stimulated with 5mM PM or with
concentrated and rediluted FasL at a final concentration of 50%.
Determination of cell survival was done as described in Fig. 1.
cells tested, addition of the radical scavengers NAC
and BPN did not influence apoptosis induced by PM
 .or FasL Fig. 4 .
4. Discussion
When treating glioma cell lines with PM the cells
undergo apoptosis. We find PM-induced apoptosis to
be inhibited by up to 30% by ActD and to be
completely blocked by costimulation with CHX.
Whether the different efficiencies of ActD and CHX
in inhibiting PM-induced cell death really represent a
clue to the mode of action of PM in this process
remains to be shown. Nonetheless, protein synthesis
as a process including both, mRNA transcription and
protein translation is an obligatory part of PM-in-
duced apoptosis. Our results are in agreement with
recent data on neurons, there apoptosis induced by
w xPM was also inhibited by CHX 19 .
Although high protein levels of the antiapoptotic
proto-oncogene bcl-2 confer resistance to different
inducers of PCD including FasL or a Fas Ab, TNF-a ,
growth factor deprivation, g-irradiation, multiple
chemotherapeutic drugs, as well as many others
w x17,20,21 , we did not find significant reduction of
PM-triggered killing of transfected cells overexpress-
ing bcl-2. This finding might reflect an apoptotic
pathway not involving bcl-2 or the need of additional
regulatory factors besides bcl-2 to prevent apoptosis
w x22 . Sufficient expression of bcl-2 to reduce apopto-
sis was assured by the reduced cell death of the bcl-2
overexpressing glioma cell lines upon exposure to
FasL. In contrast to our results, in other cell types
bcl-2 has been found to be ineffective in preventing
w xFas-mediated cell death 23 . Future experiments will
have to show whether bcl-2 interferes more effi-
ciently with PM-cytotoxicity in other cell types and
which additional cell type-specific components are
responsible for the differential protection by bcl-2
overexpression from apoptosis induced by PM or
FasL.
Enzymes of the caspase family were shown to be
key molecules involved in many apoptotic pathways.
The inhibition of caspases greatly reduces the induc-
tion of apoptosis by FasL and other stimuli including
staurosporine, cycloheximide, thapsigargin and
w xetoposide 24,25 . This is confirmed in the study
presented here. The addition of tetrapeptide-inhibitors
 .specific for caspase-1 ICE and caspase-3
 .CPP32rYama produced a marked decrease of
apoptosis induced by the FasrFasL system. By
blocking all known caspases with the general in-
hibitor zVAD-fmk, FasL-induced apoptosis is com-
pletely abolished. Induction of apoptosis by PM is
found unaffected by the specific inhibitors for cas-
pase-1 and caspase-3 and by the general caspase
inhibitor. This finding is in accordance with other
ways of inducing PCD, for example with the recently
shown induction of cell death by overexpression of
w xbax, also being independent of caspase activity 26 .
In some systems of PCD, the elimination of reac-
tive oxygen intermediates leads to inhibition of the
w xdeath program 20 . Depending on the cell types
used, Fas-mediated apoptosis has been shown to be
w x w xreduced 27 or unaffected by radical scavengers 28 .
Pre- and coincubation of the glioma cells with the
radical scavengers NAC and BPN showed no effect
on the rate of cell killing by PM or FasL.
Taken together, these findings suggest a pathway
of cell death induced by PM, which is shared in part
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with other apoptotic pathways namely the require-
ment of protein synthesis. Whereas the influence of
bcl-2 was less pronounced, other key regulators like
caspases did not modulate PM-induced apoptosis.
Thus, PM-induced apoptosis follows not yet identi-
fied apoptotic pathways which may be caused by
blocking the action of puromycin-specific compo-
nents like aminopeptidases or inhibition of transcrip-
tional processes. Further investigations will have to
prove whether the signal pathways in PM-induced
and other apoptotic processes are completely distinct
or whether they converge downstream of the cas-
pases.
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